Qure AI vs Rayscape
Two comprehensive chest imaging platforms built for settings where a radiologist may not read the film at all. Qure holds the broadest regulatory footprint in chest radiography, nine products across radiography and computed tomography, with published device dossiers and deployments in screening programmes across several countries. Rayscape is smaller with the more interesting single piece of evidence: independent evaluation in a tuberculosis screening context, which tests the product under exactly the conditions that break imaging AI, plus longitudinal comparison against a patient's prior scans. Both offer on premise deployment, which matters where images cannot leave the country. Do not compare them on findings counts, which are counted differently and mean little. Compare them on performance for the findings your population actually presents with, at your prevalence.
- The regulatory footprint across chest radiography is the broadest in the market, spanning nine products across radiography and computed tomography with published device dossiers behind them.
- It is deployed where radiologist capacity is thinnest, including public health screening programmes, so the product has been proven under the conditions that break most imaging AI.
- On premise installation is supported and stated, which removes the data transfer question rather than governing it.
- Independent evaluation in a tuberculosis screening context is a harder test than a retrospective reader study, and it is the strongest single evidence point on either record.
- Longitudinal comparison across a patient's prior scans is built in, so change over time is visible rather than each study being read in isolation.
- Both on premise and cloud integration are offered, and the findings breadth on chest radiography is substantial.
Side by Side
| Axis | Q Qure AI |
R Rayscape |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The headline findings counts these vendors publish are not comparable, because each counts differently and per finding performance varies enormously within any such list; ask both for performance on the specific findings that matter in your population.
Prevalence is the other uncontrolled variable and it is decisive here: a model validated in a high tuberculosis burden setting produces very different positive predictive values in a low prevalence one, and neither publishes performance stratified that way. Neither holds a located security attestation or trust centre, and neither publishes pricing.